Cargando…

Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND AND AIM: Acute variceal bleeding (AVB) is life-threatening. We aimed to systematically review the current evidence regarding the efficacy and safety of terlipressin for AVB in liver cirrhosis. METHODS: We searched the PubMed, EMBASE, and Cochrane Library databases. The reference list was...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xinmiao, Tripathi, Dhiraj, Song, Tingxue, Shao, Lichun, Han, Bing, Zhu, Jia, Han, Dan, Liu, Fufang, Qi, Xingshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283114/
https://www.ncbi.nlm.nih.gov/pubmed/30508958
http://dx.doi.org/10.1097/MD.0000000000013437
_version_ 1783379126392979456
author Zhou, Xinmiao
Tripathi, Dhiraj
Song, Tingxue
Shao, Lichun
Han, Bing
Zhu, Jia
Han, Dan
Liu, Fufang
Qi, Xingshun
author_facet Zhou, Xinmiao
Tripathi, Dhiraj
Song, Tingxue
Shao, Lichun
Han, Bing
Zhu, Jia
Han, Dan
Liu, Fufang
Qi, Xingshun
author_sort Zhou, Xinmiao
collection PubMed
description BACKGROUND AND AIM: Acute variceal bleeding (AVB) is life-threatening. We aimed to systematically review the current evidence regarding the efficacy and safety of terlipressin for AVB in liver cirrhosis. METHODS: We searched the PubMed, EMBASE, and Cochrane Library databases. The reference list was also hand-searched. Using a random-effect model, we combined the data obtained according to the different time points when the events developed. Odds ratio (OR) and weighted mean difference (WMD) were calculated. Quality of evidence was evaluated by the GRADE methodology. RESULTS: Thirty randomized controlled trials with 3344 patients were included. Compared with no vasoactive drug, terlipressin significantly improved the control of bleeding within 48 hours (OR = 2.94, P = .0008) and decreased the in-hospital mortality (OR = 0.31, P = .008). Compared with somatostatin, terlipressin had a significantly higher risk of complications (OR = 2.44, P = .04). Compared with octreotide, terlipressin had a significantly inferior control of bleeding within 24 hours (OR = 0.37, P = .007). Compared with vasopressin, terlipressin had a significantly lower risk of complications (OR = 0.15, P = .02). Compared with terlipressin combined with endoscopic variceal ligation, terlipressin alone had significantly higher 5-day treatment failure (OR = 14.46, P = .01) and transfusion requirements within 49 to 120 hours (WMD = 1.20, P = .002). No outcome was significantly different between terlipressin and sclerotherapy. Compared with balloon tamponade, terlipressin significantly decreased the 30-day rebleeding (OR = 0.05, P = .001) and transfusion requirements (WMD = −2.70, P = .02). Quality of evidence was very low to moderate. CONCLUSION: Our findings were in accordance with the current recommendations regarding terlipressin for the treatment of AVB in cirrhosis. However, due to low quality of evidence, further studies are recommended.
format Online
Article
Text
id pubmed-6283114
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-62831142018-12-26 Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials Zhou, Xinmiao Tripathi, Dhiraj Song, Tingxue Shao, Lichun Han, Bing Zhu, Jia Han, Dan Liu, Fufang Qi, Xingshun Medicine (Baltimore) Research Article BACKGROUND AND AIM: Acute variceal bleeding (AVB) is life-threatening. We aimed to systematically review the current evidence regarding the efficacy and safety of terlipressin for AVB in liver cirrhosis. METHODS: We searched the PubMed, EMBASE, and Cochrane Library databases. The reference list was also hand-searched. Using a random-effect model, we combined the data obtained according to the different time points when the events developed. Odds ratio (OR) and weighted mean difference (WMD) were calculated. Quality of evidence was evaluated by the GRADE methodology. RESULTS: Thirty randomized controlled trials with 3344 patients were included. Compared with no vasoactive drug, terlipressin significantly improved the control of bleeding within 48 hours (OR = 2.94, P = .0008) and decreased the in-hospital mortality (OR = 0.31, P = .008). Compared with somatostatin, terlipressin had a significantly higher risk of complications (OR = 2.44, P = .04). Compared with octreotide, terlipressin had a significantly inferior control of bleeding within 24 hours (OR = 0.37, P = .007). Compared with vasopressin, terlipressin had a significantly lower risk of complications (OR = 0.15, P = .02). Compared with terlipressin combined with endoscopic variceal ligation, terlipressin alone had significantly higher 5-day treatment failure (OR = 14.46, P = .01) and transfusion requirements within 49 to 120 hours (WMD = 1.20, P = .002). No outcome was significantly different between terlipressin and sclerotherapy. Compared with balloon tamponade, terlipressin significantly decreased the 30-day rebleeding (OR = 0.05, P = .001) and transfusion requirements (WMD = −2.70, P = .02). Quality of evidence was very low to moderate. CONCLUSION: Our findings were in accordance with the current recommendations regarding terlipressin for the treatment of AVB in cirrhosis. However, due to low quality of evidence, further studies are recommended. Wolters Kluwer Health 2018-11-30 /pmc/articles/PMC6283114/ /pubmed/30508958 http://dx.doi.org/10.1097/MD.0000000000013437 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Zhou, Xinmiao
Tripathi, Dhiraj
Song, Tingxue
Shao, Lichun
Han, Bing
Zhu, Jia
Han, Dan
Liu, Fufang
Qi, Xingshun
Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials
title Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials
title_full Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials
title_fullStr Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials
title_full_unstemmed Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials
title_short Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials
title_sort terlipressin for the treatment of acute variceal bleeding: a systematic review and meta-analysis of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283114/
https://www.ncbi.nlm.nih.gov/pubmed/30508958
http://dx.doi.org/10.1097/MD.0000000000013437
work_keys_str_mv AT zhouxinmiao terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT tripathidhiraj terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT songtingxue terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT shaolichun terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT hanbing terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT zhujia terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT handan terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT liufufang terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT qixingshun terlipressinforthetreatmentofacutevaricealbleedingasystematicreviewandmetaanalysisofrandomizedcontrolledtrials